#Checkmate 274 plus

The average time patients lived with Opdivo was 12.2 months, compared with 9.4 months with docetaxel (another cancer medicine).įor squamous NSCLC, a study involving 272 adults showed that patients given Opdivo lived for 9.2 months after starting treatment, compared with 6.0 months in patients given docetaxel.

#Checkmate 274 plus

Improvements in the time patients lived without their disease getting worse when treated with Opdivo plus ipilimumab relative to Opdivo used on its own were only seen for patients whose cancer cells produced low levels of PD-L1.įor non-squamous NSCLC, one main study involved 582 adults whose disease had got worse despite previous treatments. The study included patients whose cancer cells produced high levels of PD-L1 as well as patients whose cancer cells produced low levels of PD-L1. Patients given Opdivo plus ipilimumab lived for 11.5 months without their disease getting worse compared with 6.9 months for patients given only Opdivo and 2.9 months for patients given only ipilimumab.More patients were alive after 2 years with Opdivo and ipilimumab treatment (64%) than with Opdivo alone (59%) or ipilimumab alone (45%). Patients treated with Opdivo lived on average 31 months before the cancer came back, or a new melanoma occurred or they died, compared with 24 months for patients treated with ipilimumab.Ī fourth study in 945 previously untreated adults with advanced melanoma investigated Opdivo in combination with ipilimumab, Opdivo used alone or ipilimumab used alone. Around 32% (38 out of 120) of patients given Opdivo responded to treatment and had a reduction in their tumours, compared with about 11% (5 out of 47) of patients given a treatment chosen by their doctor (dacarbazine or a combination of carboplatin and paclitaxel).Ī third study in 906 adults with melanoma who had surgery and who were at high risk of the cancer coming back compared Opdivo with ipilimumab. In the second study, 405 patients with advanced melanoma whose disease had got worse despite previous treatment with a cancer medicine were followed up for at least 6 months. The first study, involving 418 previously untreated advanced melanoma patients, found that patients treated with Opdivo lived longer than patients who received the cancer medicine dacarbazine: 73% of patients treated with Opdivo were alive after 12 months compared with 42% of patients given dacarbazine. Opdivo used on its own was studied in two main studies in adults with advanced melanoma who had not undergone surgery. Opdivo contains the active substance nivolumab. Opdivo can be used on its own and, for some cancers, it is also used together with other cancer medicines such as cabozantinib or ipilimumab. Opdivo works on cancer cells that produce a protein called PD-L1, and tests may be needed before treatment to check that treatment with Opdivo is suitable.

Opdivo is mainly used when cancers that are advanced, unresectable (cannot be removed by surgery) or have spread to other parts of the body (metastatic) or when other treatments do not work.įor melanoma, oesophageal cancer, gastro-oesophageal junction cancer and urothelial cancer, Opdivo is also used to help prevent the cancer from coming back after patients have had surgery ( adjuvant therapy). gastric (stomach), gastro-oesophageal junction or oesophageal adenocarcinoma.oesophageal cancer and gastro-oesophageal junction cancer (cancer at the junction between the stomach and the oesophagus) after chemotherapy, radiotherapy and surgery.squamous oesophageal cancer (cancer of the oesophagus, the passage from mouth to stomach).a kind of cancer of the colon or rectum (lower part of the gut) that is described as microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR).malignant pleural mesothelioma (a cancer of the lining of the lungs).urothelial cancer, a cancer of the bladder and urinary tract.squamous cell cancer of the head and neck (SCCHN).classical Hodgkin lymphoma, a cancer of the lymphocytes (a type of white blood cell).advanced renal cell carcinoma, a kidney cancer.

a lung cancer called non-small cell lung cancer (NSCLC).Opdivo is a cancer medicine used in adults to treat the following: